2018
Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment
Han C, Bellone S, Zammataro L, Schwartz PE, Santin AD. Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment. Gynecologic Oncology Reports 2018, 25: 41-44. PMID: 29946554, PMCID: PMC6014583, DOI: 10.1016/j.gore.2018.05.011.Peer-Reviewed Original ResearchLow-grade serous ovarian carcinomaTreatment optionsHormonal treatmentRecurrent low-grade serous ovarian cancerRecurrent low-grade serous ovarian carcinomaLow-grade serous ovarian cancerDramatic clinical responseDrug-related toxicityEffective treatment optionNew treatment optionsSerial CT scansSerous ovarian cancerSerous ovarian carcinomaMitogen-activated protein kinase inhibitorOral steroidsRECIST 1.1Clinical responseMultiple chemotherapyOvarian carcinomaTarget lesionsOvarian cancerCT scanResponse durationBinimetinibKRAS G12Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report
Han C, Bellone S, Schwartz PE, Govindan SV, Sharkey RM, Goldenberg DM, Santin AD. Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report. Gynecologic Oncology Reports 2018, 25: 37-40. PMID: 29977989, PMCID: PMC6030029, DOI: 10.1016/j.gore.2018.05.009.Peer-Reviewed Original ResearchUterine serous carcinomaSacituzumab govitecanAntibody-drug conjugatesSerous carcinomaTreatment optionsNovel antibody-drug conjugateTreatment-resistant diseaseImpressive clinical responsesSignificant adverse eventsEffective treatment optionNew treatment optionsSerial CT scansUSC patientsAdverse eventsClinical responseMultiple chemotherapyAggressive variantCase reportUterine cancerClinical trialsCT scanDramatic responseSurface antigenTrop-2Chemotherapy
2013
A phase I study of birinapant (TL32711) combined with multiple chemotherapies evaluating tolerability and clinical activity for solid tumor patients.
Amaravadi R, Senzer N, Martin L, Schilder R, LoRusso P, Papadopoulos K, Weng D, Graham M, Adjei A. A phase I study of birinapant (TL32711) combined with multiple chemotherapies evaluating tolerability and clinical activity for solid tumor patients. Journal Of Clinical Oncology 2013, 31: 2504-2504. DOI: 10.1200/jco.2013.31.15_suppl.2504.Peer-Reviewed Original ResearchCarboplatin/paclitaxelDose-limiting toxicityLiposomal doxorubicinMultiple chemotherapyDose escalationClinical benefitExcellent tolerabilityClinical activityClinical studiesRefractory solid tumorsPhase 1 studySolid tumor patientsFurther clinical studiesAnti-tumor synergyHighest dose levelNotable clinical activityApoptotic pathway activationG regimenStable diseaseStandard dosingProgressive diseasePartial responseBell's palsyTolerable combinationReversible toxicity
2005
Yttrium 90 Resin Microspheres for the Treatment of Unresectable Colorectal Hepatic Metastases after Failure of Multiple Chemotherapy Regimens: Preliminary Results
Murthy R, Xiong H, Nunez R, Cohen AC, Barron B, Szklaruk J, Madoff DC, Gupta S, Wallace MJ, Ahrar K, Hicks ME. Yttrium 90 Resin Microspheres for the Treatment of Unresectable Colorectal Hepatic Metastases after Failure of Multiple Chemotherapy Regimens: Preliminary Results. Journal Of Vascular And Interventional Radiology 2005, 16: 937-945. PMID: 16002501, DOI: 10.1097/01.rvi.0000161142.12822.66.Peer-Reviewed Original ResearchConceptsUnresectable colorectal hepatic metastasesColorectal hepatic metastasesHepatic metastasesSIR-SpheresMultiple chemotherapySingle infusionPrescribed doseYttrium-90 resin microspheresEmbolic arterial occlusionHepatic metastatic diseaseMultiple chemotherapy regimensLiver-directed therapiesCarcinoembryonic antigen levelYttrium-90 microspheresCompletion of treatmentMedian survival timeHepatic tumor volumeBilobar diseaseIntrahepatic progressionRadiologic responseUnilobar diseaseAdvanced diseaseChemotherapy regimenChemotherapy regimensIntraarterial chemotherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply